Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Articles

On Mar. 29, 2012, the Generic Pharmaceutical Association reiterated its call for Congress to move forward with user-fee proposals for generic drugs and biosimilar products.

GPhA Urges Congress to Move Ahead on Generic-Drug and Biosimilar User Fees

In Part III of a three-part article, the authors examine various degradation routes of APIs, impurities arising from interactions in formulations, metabolite impurities, various analytical methods to measure impuritie, and ways to control impurities.

Evaluating Impurities in Drugs (Part III of III)

With financing constrained, biotechnology firms must find ways to sustain innovation.

A Sustainable Biotech Path

How to use geographic diversification and legacy technology transfers to avoid product shortages.

Managing Product Supply Risks

In our tablet coating process, we are losing up to 15% of our coating solution in each processing run. What can we do to prevent this problem in order to reduce waste and increase our cost efficiency?

Reducing Waste in Tablet Coating

Amy Ritter was Scientific Editor, BioPharm International.

On Mar. 7, 2012, GE Healthcare announced an agreement to acquire Xcellerex, a supplier of manufacturing technologies for the biopharmaceutical industry, for an undisclosed amount.

GE Healthcare to Acquire Xcellerex

AstraZeneca Files Suit Against FDA; Pfizer, Biocon Terminate Biosimilar Alliance; and More.

Week of Mar. 12, 2012: AstraZeneca Files Suit Against FDA; Pfizer, Biocon Terminate Biosimilar Alliance; and More

CML - Solid State Chemistry

BASi Restructures; Celerion, Ricerca Biosciences Form Biosimilars Alliance; and More.

Week of Mar. 5, 2012: BASi Restructures; Celerion, Ricerca Biosciences Form Biosimilars Alliance; and More

The Bulk Pharmaceuticals Task Force, an affiliate of the Society of Chemical Manufacturers and Affiliates (SOCMA), issued its support for the introduction of a House bill, the Generic Drug and Biosimilar User Fee Act (HR 3988), which SOCMA says will help to achieve parity between foreign and domestic firms.